- Home
- ANTX vs RADX Comparison
ANTX vs RADX Comparison
Compare ANTX & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- RADX
- Stock Information
- Founded
- ANTX 2017
- RADX 2021
- Country
- ANTX United States
- RADX Australia
- Employees
- ANTX N/A
- RADX N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- ANTX Health Care
- RADX
- Exchange
- ANTX Nasdaq
- RADX NYSE
- Market Cap
- ANTX 37.6M
- RADX 38.4M
- IPO Year
- ANTX 2022
- RADX N/A
- Fundamental
- Price
- ANTX $1.41
- RADX $5.42
- Analyst Decision
- ANTX Hold
- RADX Strong Buy
- Analyst Count
- ANTX 5
- RADX 1
- Target Price
- ANTX $3.50
- RADX $15.00
- AVG Volume (30 Days)
- ANTX 168.1K
- RADX 480.6K
- Earning Date
- ANTX 03-27-2025
- RADX 02-26-2025
- Dividend Yield
- ANTX N/A
- RADX N/A
- EPS Growth
- ANTX N/A
- RADX N/A
- EPS
- ANTX N/A
- RADX N/A
- Revenue
- ANTX N/A
- RADX $204,609.00
- Revenue This Year
- ANTX N/A
- RADX N/A
- Revenue Next Year
- ANTX N/A
- RADX N/A
- P/E Ratio
- ANTX N/A
- RADX N/A
- Revenue Growth
- ANTX N/A
- RADX N/A
- 52 Week Low
- ANTX $0.87
- RADX $3.55
- 52 Week High
- ANTX $3.88
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- ANTX 72.16
- RADX N/A
- Support Level
- ANTX $1.09
- RADX N/A
- Resistance Level
- ANTX $1.39
- RADX N/A
- Average True Range (ATR)
- ANTX 0.06
- RADX 0.00
- MACD
- ANTX 0.03
- RADX 0.00
- Stochastic Oscillator
- ANTX 94.20
- RADX 0.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.